Cargando…

Correction: The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models

Detalles Bibliográficos
Autores principales:	Kim, Sunkyu, Tiedt, Ralph, Loo, Alice, Horn, Thomas, Delach, Scott, Kovats, Steven, Haas, Kristy, Engstler, Barbara Schacher, Cao, Alexander, Pinzon-Ortiz, Maria, Mulford, Iain, Acker, Michael G., Chopra, Rajiv, Brain, Christopher, Tomaso, Emmanuelle di, Sellers, William R., Caponigro, Giordano
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2020
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7147087/ https://www.ncbi.nlm.nih.gov/pubmed/32292577 http://dx.doi.org/10.18632/oncotarget.27407

Ejemplares similares

The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models
por: Kim, Sunkyu, et al.
Publicado: (2018)

Pharmacodynamics effects of CDK4/6 inhibitor LEE011 (ribociclib) in high-risk, localised prostate cancer: a study protocol for a randomised controlled phase II trial (LEEP study: LEE011 in high-risk, localised Prostate cancer)
por: Scheinberg, Tahlia, et al.
Publicado: (2020)

Antitumoral Activity of the MEK Inhibitor Trametinib (TMT212) Alone and in Combination with the CDK4/6 Inhibitor Ribociclib (LEE011) in Neuroendocrine Tumor Cells In Vitro
por: Jin, Xi-Feng, et al.
Publicado: (2021)

LEE011 and ruxolitinib: a synergistic drug combination for natural killer/T-cell lymphoma (NKTCL)
por: Hee, Yan Ting, et al.
Publicado: (2018)

Discovery and development of novel therapies in advanced breast cancer: rapid development of ribociclib
por: Germa, C., et al.
Publicado: (2017)

Safety and efficacy of cyclin-dependent kinase inhibitor rechallenge following ribociclib-induced limiting hypertransaminasemia
por: Fuentes-Antrás, Jesús, et al.
Publicado: (2020)

Biological Effects of Cyclin-Dependent Kinase Inhibitors Ribociclib, Palbociclib and Abemaciclib on Breast Cancer Bone Microenvironment
por: Iuliani, Michele, et al.
Publicado: (2022)

Combination therapy with BYL719 and LEE011 is synergistic and causes a greater suppression of p-S6 in triple negative breast cancer
por: Yuan, Yuan, et al.
Publicado: (2019)

Inhibition of the CDK4/6-Cyclin D-Rb Pathway by Ribociclib Augments Chemotherapy and Immunotherapy in Renal Cell Carcinoma
por: Chen, Dehong, et al.
Publicado: (2020)

Molecular mechanism of G(1) arrest and cellular senescence induced by LEE011, a novel CDK4/CDK6 inhibitor, in leukemia cells
por: Tao, Yan-Fang, et al.
Publicado: (2017)

Microcosm 2.011
por: CERN Bulletin
Publicado: (2011)

Preclinical Evaluation of the Association of the Cyclin-Dependent Kinase 4/6 Inhibitor, Ribociclib, and Cetuximab in Squamous Cell Carcinoma of the Head and Neck
por: van Caloen, Gabrielle, et al.
Publicado: (2021)

Ribociclib Induced Photosensitive Skin Lesions
por: Verma, Vaishnavi, et al.
Publicado: (2022)

Combination of Ribociclib and Gemcitabine for the Treatment of Medulloblastoma
por: Pribnow, Allison, et al.
Publicado: (2022)

Recent advances of cyclin-dependent kinases as potential therapeutic targets in HR+/HER2− metastatic breast cancer: a focus on ribociclib
por: Edessa, Dumessa, et al.
Publicado: (2017)

Characterization of the Synergistic Inhibition of I(K(erg)) and I(K(DR)) by Ribociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor
por: Liu, Pin-Yen, et al.
Publicado: (2020)

Ribociclib-induced Vitiligo: a Case Report
por: Silvestre Torner, Nicolás, et al.
Publicado: (2022)

P011 Antifungal lock therapy
por: Koparkar, Vidyullata, et al.
Publicado: (2022)

Case Report of Probable DRESS Syndrome Associated with Ribociclib
por: Carneiro, Florian, et al.
Publicado: (2023)

On the Lee-model
por: Kroll, N M
Publicado: (1958)

Jooyoung Lee
por: Lee, Jooyoung
Publicado: (2023)

David Lees
Publicado: (1934)

CMS Event Displays for EXO-19-011
por: CMS Collaboration
Publicado: (2020)

P03-011 - Differential for granulomatosis with polyangiitis
por: Rawn, SM, et al.
Publicado: (2013)

P01-011 – Colchicine compliance and amyloidosis
por: Ozdogan, H, et al.
Publicado: (2013)

Ribociclib: a valuable addition to treatment options in breast cancer?
por: Bartsch, Rupert
Publicado: (2017)

Ribociclib and palbociclib-induced erythema multiforme: a case report
por: Vrana, Eleni, et al.
Publicado: (2022)

Phase I trial of ribociclib with platinum chemotherapy in ovarian cancer
por: Coffman, Lan G., et al.
Publicado: (2022)

Differences in metabolic transport and resistance mechanisms of Abemaciclib, Palbociclib, and Ribociclib
por: Zhu, Zhimin, et al.
Publicado: (2023)

Quiéres dinero? Lee-- /
por: González, Juan T.
Publicado: (2001)

Lee de Virginia
por: Freeman, Douglas Southall
Publicado: (1965)

Despierta y lee
por: Savater, Fernando 1947-
Publicado: (1998)

Tim Berners-Lee
Publicado: (2004)

Vote Berners-Lee
por: Harvey, F
Publicado: (2004)

An alternative view of LEE
por: Ranucci, Gioacchino
Publicado: (2011)

T.D. Lee
por: CERN PhotoLab
Publicado: (1965)

Lee's Lectures on Syphilis
Publicado: (1876)

Lee's Surgical Pathology
Publicado: (1871)

Edwin Leonard Lees
Publicado: (1949)

Dr. Hallvard Lee
Publicado: (1907)

Cannot write session to /tmp/vufind_sessions/sess_u4g57gi5p9t405runfhv9s6d9a